Live Analyst Rating Changes 3274 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Roy Buchanan
CJ
Roy Buchanan
Citizens JMP
Wall Street Analyst
★★★☆☆
#1764
on 13Foresight · ranked by our own returns
65%
Success Rate
+29.5%
Average Return
11 of 17 calls profitable · -246.3% vs benchmark
📈 Across the calls we could measure, roughly 65% of Roy Buchanan's ratings turned a profit when each position was held for 1 year — averaging +29.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

10 Buy 0 Hold 0 Sell
Roy's Stock Coverage 18 ratings · 2026-06-27
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ASMB
Assembly Biosciences
 Sep 24, 2025 BUY Strong Buy
+28.8% avg upside
10 analysts
$38.00
42.10% Upside
 +11.7%
INO
Inovio Pharmaceuticals
 Aug 13, 2025 BUY Strong Buy
+822.0% avg upside
19 analysts
$12.00
990.99% Upside
 -35.3%
ENTA
Enanta Pharmaceuticals
 Aug 12, 2025 BUY Buy
+134.5% avg upside
17 analysts
$25.00
78.62% Upside
 +105.6%
PYPD
PolyPid
 Jun 17, 2025 BUY Strong Buy
+248.5% avg upside
7 analysts
$14.00
194.68% Upside
 +33.7%
ANTX
AN2 Therapeutics, Inc.
 May 05, 2025 BUY Buy
+68.3% avg upside
7 analysts
$2.00
61.58% Downside
 +290.8%
ABUS
Arbutus Biopharma
 Mar 31, 2025 BUY Strong Buy
+93.0% avg upside
15 analysts
$5.00
9.18% Upside
 +28.9%
IBIO
Ibio
 Nov 03, 2023 HOLD Strong Buy
+248.9% avg upside
11 analysts
 — -54.0%
ARGX
Argenx Se
 Mar 02, 2023 BUY Strong Buy
-15.8% avg upside
46 analysts
$448.00
49.41% Downside
 +14.0%
PRQR
ProQR
 Sep 29, 2016 HOLD Strong Buy
+652.4% avg upside
18 analysts
 — -28.1%
NTLA
Intellia Therapeutics
 Sep 28, 2016 BUY Buy
+136.8% avg upside
37 analysts
$29.00
73.81% Upside
 ·
IONS
Ionis Pharmaceuticals
 Sep 28, 2016 BUY Strong Buy
+4.1% avg upside
43 analysts
$47.00
42.12% Downside
 +45.3%
ALNY
Alnylam Pharma
 Sep 28, 2016 HOLD Strong Buy
+17.6% avg upside
51 analysts
$74.00
74.58% Downside
 +54.3%
SGMO
Sangamo Therapeutics
 Aug 04, 2016 HOLD Buy
+15048.7% avg upside
16 analysts
 — +78.0%
ELDN
Eledon Pharmaceuticals
 Jul 26, 2016 HOLD Strong Buy
+324.9% avg upside
10 analysts
 — -47.9%
ALDX
Aldeyra Therapeutics
 Feb 29, 2016 BUY Strong Buy
+775.0% avg upside
21 analysts
$25.00
1266.20% Upside
 +1.0%
GERN
Geron
 Dec 16, 2015 BUY Strong Buy
+221.0% avg upside
19 analysts
$6.50
392.45% Upside
 -54.7%
VTVT
vTv Therapeutics
 Dec 16, 2015 BUY Strong Buy
-8.1% avg upside
12 analysts
$21.00
40.04% Downside
 -18.2%
CORT
Corcept Therapeutics
 Dec 16, 2015 BUY Buy
-50.1% avg upside
15 analysts
$8.00
90.89% Downside
 +76.4%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Roy Buchanan — Frequently Asked Questions
How accurate are Roy Buchanan's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Roy's ratings were profitable over a one-year hold, with an average return of +29.5% per rating, or -246.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Roy ranked on 13Foresight?
Roy Buchanan is currently ranked #1764 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Roy cover?
Roy most recently has ratings on ASMB, INO, ENTA, PYPD, ANTX, ABUS, IBIO, ARGX, PRQR, NTLA, IONS, ALNY and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.